NICOMOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C34H32N4O9
Molecular Weight	640.6393
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1C(COC(=O)C2=CN=CC=C2)(COC(=O)C3=CN=CC=C3)CCCC1(COC(=O)C4=CN=CC=C4)COC(=O)C5=CN=CC=C5

InChI

InChIKey=VRAHPESAMYMDQI-UHFFFAOYSA-N

InChI=1S/C34H32N4O9/c39-28(24-6-1-12-35-16-24)44-20-33(21-45-29(40)25-7-2-13-36-17-25)10-5-11-34(32(33)43,22-46-30(41)26-8-3-14-37-18-26)23-47-31(42)27-9-4-15-38-19-27/h1-4,6-9,12-19,32,43H,5,10-11,20-23H2

HIDE SMILES / InChI

Description
Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/CHOLEXAMIN_Tablets.pdf
Curator's Comment: Description was created based on several sources, including http://www.genome.jp/dbget-bin/www_bget?D01291

Hypolipidemic agent, Nicomol is an ingredient of Cholexamin in Japan. Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched by KYORIN Pharmaceutical in 1971. It is indicated for the treatment of hyperlipemia, improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Carnitine O-acetyltransferase 18 Target ID: Q704S8 Gene ID: 311849.0 Gene Symbol: Crat Target Organism: Rattus norvegicus (Rat) Sources: http://www.ncbi.nlm.nih.gov/pubmed/6798192	Activator 1447
D-amino-acid oxidase 6 Target ID: CHEMBL5756 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6798192	Activator 1447
Cholesterol biosynthesis 1 Target ID: WP1795 Sources: http://www.ncbi.nlm.nih.gov/pubmed/227232	Modulator 846

Conditions

Condition	Modality	Highest Phase	Product
Arrhythmia 45 Sources: http://www.ncbi.nlm.nih.gov/pubmed/201997	Preventing	Basic research	Unknown Approved Use Unknown
Hyperlipidemia 82 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/CHOLEXAMIN_Tablets.pdf	Primary	Approved 8583	Cholexamin Approved Use INDICATIONS: Hyperlipemia Improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome Launch Date 1970
Limb arterial occlusive disease 1 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/CHOLEXAMIN_Tablets.pdf	Primary	Approved 8583	Cholexamin Approved Use INDICATIONS: Hyperlipemia Improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome Launch Date 1969
Raynaud syndrome 1 Sources: http://www.kyorin-pharm.co.jp/prodinfo/medicine/pdf/CHOLEXAMIN_Tablets.pdf	Primary	Approved 8583	Cholexamin Approved Use Hyperlipemia Improvement in peripheral circulatory disorder resulting from the following diseases Chilblain, limb arterial occlusive disease (obstructive thromboarteritis and arteriosclerosis obliterans), Raynaud syndrome Launch Date 1970

Doses

Dose	Population	Adverse events
1200 mg 3 times / day multiple, oral Highest studied dose Dose: 1200 mg, 3 times / day Route: oral Route: multiple Dose: 1200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6456646/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/6456646/	Sources: https://pubmed.ncbi.nlm.nih.gov/6456646/

PubMed

Title	Date	PubMed
Effects of some hypolipidemic drugs on biochemical values and on hepatic peroxisomal enzymes of normolipemic rat.	1981-10	6798192
Effect of nicomol on high density lipoprotein (HDL) subfractions, HDL2e and HDL3e, separated by electrophoresis.	1981-04	6456646
Effect of nicomol on HDL cholesterol level.	1979-08	227232
Arrhythmogenic effects of acute free fatty acid mobilization on ischemic heart.	1976-05-26	201997

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage of this product for oral use is 200 to 400 mg of Nicomol three times daily after meals.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

CHOLEXAMIN

Preferred Name

English

NICOMOL

Official Name

English

NICOMOL [MART.]

Common Name

English

NICOMOL [MI]

Common Name

English

Nicomol [WHO-DD]

Common Name

English

nicomol [INN]

Common Name

English

NICOMOL [JAN]

Common Name

English

2-HYDROXY-1,1,3,3-CYCLOHEXANETETRAMETHANOL 1,1,3,3-TETRANICOTINATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98151